Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Kuehl, P. M., Zhang, J., Lin, Y., Lamba, J. K., Assem, M., Schuetz, J. D., Watkins, P. B., Daly, A. K., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,172

Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

Ekberg, H., Junior, H. T. S., Demirbas, A., Vitko, S., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyo, J. M., Frei, U. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,814

Genetic contribution to variable human CYP3A-mediated metabolism

Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 987

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Vincenti, F. G., Charpentier, B., Vanrenterghem, Y. F. C., Rostaing, L. P. E., Bresnahan, B. A., Darji, P., Massari, P. U., Mondragón-Ramírez, G., Agarwal, M., Russo, G. D., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 958

Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal

Lamb, K. E., Lodhi, S. A., & Meier-Kriesche, H.-U. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03283.x · Cited by 934

Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.

Fruman, D. A., Klee, C. B., Bierer, B. E., & Burakoff, S. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3686 · Cited by 823

Belatacept and Long-Term Outcomes in Kidney Transplantation

Vincenti, F. G., Rostaing, L. P. E., Grinyo, J. M. B., Rice, K. M., Steinberg, S., Gaite, L., Moal, M., Mondragón-Ramírez, G., Kothari, J., Polinsky, M. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506027 · Cited by 789

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Birdwell, K. A., Decker, B. S., Barbarino, J. M., Peterson, J., Stein, C., Sadée, W., Wang, D., Vinks, A. A. T. M. M., He, Y., Swen, J. J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.113 · Cited by 751

The genetic determinants of the CYP3A5 polymorphism

Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nussler, A. K., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673

Rejection of the Kidney Allograft

Nankivell, B. J., & Alexander, S. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902927 · Cited by 605

Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls

Edelbroek, P. M., van der Heijden, J., & Stolk, L. M. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819e91ce · Cited by 513

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

Wallemacq, P. E., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A. E., Kuypers, D. R. J., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

Thervet, É., Loriot, M., Barbier, S., Büchler, M., Ficheux, M., Choukroun, G. J., Toupance, O., Touchard, G., Alberti, C., Pogamp, P. L., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.17 · Cited by 368

Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

Ekberg, H., Bernasconi, C., Junior, H. T. S., Vitko, S., Hugo, C., Demirbas, A., Reyes‐Acevedo, R., Grinyo, J. M., Frei, U. A., Vanrenterghem, Y. F. C., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02726.x · Cited by 334

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

Neuberger, J., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., Geest, S. D., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 327

The temporal profile of calcineurin inhibition by cyclosporine in vivo.

Halloran, P., Helms, L., Kung, L., & Noujaim, J. (1999) · Transplantation · doi:10.1097/00007890-199911150-00023 · Cited by 326

Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus

Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 324

RELATIONSHIP OF FK506 WHOLE BLOOD CONCENTRATIONS AND EFFICACY AND TOXICITY AFTER LIVER AND KIDNEY TRANSPLANTATION

Kershner, R. P., & Fitzsimmons, W. E. (1996) · Transplantation · doi:10.1097/00007890-199610150-00009 · Cited by 310

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*

Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q. A., Dressler, D. E., Lee, J. W., Roberts, J. P., & Hébert, M. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90150-8 · Cited by 269

High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation

Borra, L. C. P., Roodnat, J. I., Kal, J., Mathôt, R. A. A., Weimar, W. W., & van Gelder, T. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq096 · Cited by 256

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165613 · Cited by 246

Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients

Kuypers, D. R. J., Peeters, P. C., Sennesael, J. J., Kianda, M. N., Vrijens, B., Kristanto, P., Dobbels, F., Vanrenterghem, Y. F. C., & Kanaan, N. (2012) · Transplantation · doi:10.1097/tp.0b013e3182725532 · Cited by 228

AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATION

Laskow, D. A., Vincenti, F. G., Neylan, J. F., Mendez, R., & Matas, A. J. (1996) · Transplantation · doi:10.1097/00007890-199610150-00005 · Cited by 219

Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation

Sikma, M. A., van Maarseveen, E. M., van de Graaf, E. A., Kirkels, J. H., Verhaar, M. C., Donker, D. W., Kesecioğlu, J., & Meulenbelt, J. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13309 · Cited by 196

Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure

Sapir‐Pichhadze, R., Wang, Y., Famure, O., Li, Y., & Kim, S. J. (2013) · Kidney International · doi:10.1038/ki.2013.465 · Cited by 190

Low systemic exposure to tacrolimus correlates with acute rejection

Undre, N. A., van Hooff, J. P., Christiaans, M. H. L., Vanrenterghem, Y. F. C., Donck, J., Heeman, U., Kohnle, M., ZANKER, B., Land, W. G., Morales, J. M., et al. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01633-9 · Cited by 190

Therapeutic drug monitoring of tacrolimus with the dried blood spot method

Hoogtanders, K., van der Heijden, J., Christiaans, M. H. L., Edelbroek, P. M., van Hooff, J. P., & Stolk, L. M. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.11.023 · Cited by 185

Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children

Pollock‐BarZiv, S. M., Finkelstein, Y., Manlhiot, C., Dipchand, A. I., Hébert, D., Ng, V. L., Solomon, M. P., McCrindle, B. W., & Grant, D. R. (2010) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2010.01409.x · Cited by 177

One-Year Results with Extended-Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients

Junior, H. T. S., Yang, H. C., Abouljoud, M. S., Kuo, P. C., Wisemandle, K., Bhattacharya, P., Dhadda, S., Holman, J., Fitzsimmons, W. E., & First, M. R. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01661.x · Cited by 177

Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology

Nankivell, B. J., P’ng, C. H., O’Connell, P. J., & Chapman, J. R. (2016) · Transplantation · doi:10.1097/tp.0000000000001243 · Cited by 175

Tacrolimus whole blood concentrations correlate closely to side‐effects in renal transplant recipients

Böttiger, Brattström, Tydén, Säwe, & Groth (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00007.x · Cited by 173

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation

Shuker, N., Bouamar, R., van Schaik, R. H. N., Groningen, M. C. C., Damman, J. J., Baan, C. C., van de Wetering, J., Rowshani, A. T., Weimar, W., van Gelder, T., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13691 · Cited by 172

AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients

Scholten, E. M., Cremers, S. C. L. M., Schoemaker, R. C., Rowshani, A. T., van Kan, E., den Hartigh, J., Paul, L. C., & de Fijter, J. W. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00352.x · Cited by 171

Dosing equation for tacrolimus using genetic variants and clinical factors

Passey, C., Birnbaum, A. K., Brundage, R. C., Oetting, W. S., Israni, A. K., & Jacobson, P. A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04039.x · Cited by 169

Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study

Krämer, B. K., Charpentier, B., Bäckman, L., Junior, H. T. S., Mondragón-Ramírez, G., Cassuto, É., Mourad, G., Solà, R., Rigotti, P., & Mirete, J. O. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03256.x · Cited by 168

Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation

Staatz, C. E., Taylor, P. J., & Tett, S. E. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1905 · Cited by 162

New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

de Jonge, H., Naesens, M., & Kuypers, D. R. J. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181aa36cd · Cited by 159

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials

Bouamar, R., Shuker, N., Hesselink, D. A., Weimar, W. W., Ekberg, H., Kaplan, B. E., Bernasconi, C., & van Gelder, T. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12191 · Cited by 158

Effect of a New FunctionalCYP3A4Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant Patients

Elens, L., van Schaik, R. H., Panin, N., Meyer, M. D., Wallemacq, P. E., Lison, D., Mourad, M., & Haufroid, V. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.90 · Cited by 154

Minimization of Immunosuppressive Therapy After Renal Transplantation: Results of a Randomized Controlled Trial

Vanrenterghem, Y. F. C., van Hooff, J. P., Squifflet, J., Salmela, K. T., Rigotti, P., Jindal, R. M., Pascual, J., Ekbergh, H., Sicilia, L. S., Boletis, J., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00638.x · Cited by 149

Cyclosporine Withdrawal from a Mycophenolate Mofetil–Containing Immunosuppressive Regimen

Abramowicz, D., Rial, M. D. C., Vitko, S., del Castillo, D., Manas, D., Lao, M., Gafner, N., & Wijngaard, P. L. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100844 · Cited by 140

DOSE OPTIMIZATION OF MYCOPHENOLATE MOFETIL WHEN ADMINISTERED WITH A LOW DOSE OF TACROLIMUS IN CADAVERIC RENAL TRANSPLANT RECIPIENTS

Squifflet, J.-P., ckman, L. B., Claesson, K., Dietl, K. H., Ekberg, H., Forsythe, J. L. R., Kunzendorf, U., Heemann, U. W., Land, W. G., Morales, J. M., et al. (2001) · Transplantation · doi:10.1097/00007890-200107150-00014 · Cited by 137

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations

Tang, J., Andrews, L. M., van Gelder, T., Shi, Y., van Schaik, R. H. N., Wang, L., & Hesselink, D. A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1170808 · Cited by 129

Pharmacokinetics for Once- Versus Twice-Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open-Label Trial

Włodarczyk, Z., Squifflet, J.-P., Ostrowski, M., Rigotti, P., Stefoni, S., Citterio, F., Vanrenterghem, Y. F. C., Krämer, B. K., Abramowicz, D., Oppenheimer, F., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02794.x · Cited by 127

Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation

Hsiau, M., Fernandez, H. E., Gjertson, D., Ettenger, R. B., & Tsai, E. W. (2011) · Transplantation · doi:10.1097/tp.0b013e31822dc34f · Cited by 121

Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation

Beckebaum, S., Iacob, S., Sweid, D., Sotiropoulos, G. C., Saner, F. H., Kaiser, G. M., Radtke, A., Klein, C. G., Erim, Y., Geest, S. D., et al. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01254.x · Cited by 120

Switching ST udy of Kidney TRansplant PA tients with Tremor to LCP ‐TacrO ( STRATO ): an open‐label, multicenter, prospective phase 3b study

Langone, A. J., Steinberg, S. M., Gedaly, R., Chan, L. K., Shah, T., Sethi, K. D., Nigro, V., Morgan, J. C., & STRATO Investigators (2015) · Clinical Transplantation · doi:10.1111/ctr.12581 · Cited by 119

In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

de Jonge, H., de Loor, H., Verbeke, K., Vanrenterghem, Y. F. C., & Kuypers, D. R. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.109 · Cited by 119

Factors affecting variability in distribution of tacrolimus in liver transplant recipients

Zahir, H., McCaughan, G. W., Gleeson, M., Nand, R. A., & McLachlan, A. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02008.x · Cited by 118

Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study

Capron, A., Lerut, J. P., Latinne, D., Rahier, J., Haufroid, V., & Wallemacq, P. E. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01365.x · Cited by 117

Lower Variability of Tacrolimus Trough Concentration After Conversion From Prograf to Advagraf in Stable Kidney Transplant Recipients

Wu, M., Cheng, C.-Y., Chen, C., Wu, W.-P., Cheng, C., Yu, D.-M., Chuang, Y., & Shu, K. (2011) · Transplantation · doi:10.1097/tp.0b013e3182292426 · Cited by 116

Non-Adherence and Graft Failure in Adult Liver Transplant Recipients

Lieber, S. R., & Volk, M. L. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2412-0 · Cited by 111

Lower Variability in 24-Hour Exposure During Once-Daily Compared to Twice-Daily Tacrolimus Formulation in Kidney Transplantation

Stifft, F., Stolk, L. M., Undre, N. A., van Hooff, J. P., & Christiaans, M. H. L. (2013) · Transplantation · doi:10.1097/01.tp.0000437561.31212.0e · Cited by 111

Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study

Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Dürrbach, A., Albano, L., Rivalan, J., Meur, Y. L., Essig, M., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14109 · Cited by 111

CYP3A5 and ABCB1 Polymorphisms Influence Tacrolimus Concentrations in Peripheral Blood Mononuclear Cells After Renal Transplantation

Capron, A., Mourad, M., Meyer, M. D., Pauw, L. D., Eddour, D. C., Latinne, D., Elens, L., Haufroid, V., & Wallemacq, P. E. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.43 · Cited by 110

Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.

Iwasaki, K., Shiraga, T., Nagase, K., Tozuka, Z., Kosei, N. O. D. A., Sakuma, S., FUJITSU, T., Shimatani, K., Sato, A., & Fujioka, M. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08219-4 · Cited by 106

Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients

Staatz, C. E., & Tett, S. E. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0282-2 · Cited by 99

Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Brooks, E., Tett, S. E., Isbel, N. M., & Staatz, C. E. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0396-1 · Cited by 98

Renal Allograft Dysfunction Associated with Rifampin–Tacrolimus Interaction

Chenhsu, R.-Y., Loong, C., Chou, M.-H., Lin, M.-F., & Yang, W. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19069 · Cited by 96

Patterns of End-Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors

Anjum, S. K., Muzaale, A. D., Massie, A. B., Bae, S., Luo, X., Grams, M. E., Lentine, K. L., Garg, A. X., & Segev, D. L. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13917 · Cited by 96

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach

Andreu, F., Colom, H., Elens, L., van Gelder, T., van Schaik, R. H. N., Hesselink, D. A., Bestard, O., Torrás, J., Cruzado, J. M., Grinyo, J. M., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0491-3 · Cited by 95

Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A

Giese, T., Zeier, M. G., Schemmer, P., Uhl, W., Schoels, M., Dengler, T. J., Buechler, M. W., & Meuer, S. C. (2004) · Transplantation · doi:10.1097/01.tp.0000109260.00094.01 · Cited by 94

Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients

Fukudo, M., Yano, I., Masuda, S., Fukatsu, S., KATSURA, T., Ogura, Y., Oike, F., TAKADA, Y., Tanaka, K., & Inui, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.008 · Cited by 89

Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection

Borobia, A. M., Romero, I. R., Jiménez, C., Gil, F., Ramı́rez, E., de Gracia, R., Escuín, F., González, E., & Carcas, A. J. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181a8f02a · Cited by 83

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation

Andrews, L. M., Hesselink, D. A., van Gelder, T., Koch, B. C. P., Cornelissen, E. A. M., Brüggemann, R. J. M., van Schaik, R. H. N., de Wildt, S. N., Cransberg, K., & de Winter, B. C. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0567-8 · Cited by 83

Genotype-guided tacrolimus dosing in African-American kidney transplant recipients

Sanghavi, K., Brundage, R. C., Miller, M. B., Schladt, D. P., Israni, A. K., Guan, W., Oetting, W. S., Mannon, R. B., Remmel, R. P., Matas, A. J., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.87 · Cited by 79

Impact of Tacrolimus Intraindividual Variability and CYP3A5 Genetic Polymorphism on Acute Rejection in Kidney Transplantation

Ro, H., Min, S., Yang, J., Moon, K. C., Kim, Y. S., Kim, S. J., Ahn, C., & Ha, J. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182731809 · Cited by 79

Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs

Picard, N., Bergan, S., Marquet, P., van Gelder, T., Wallemacq, P. E., Hesselink, D. A., & Haufroid, V. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000255 · Cited by 75

A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation

de Graav, G. N., Baan, C. C., Groningen, M. C. C., Kraaijeveld, R., Dieterich, M., Verschoor, W., von der Thüsen, J. H., Roelen, D. L., Cadogan, M., van de Wetering, J., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001755 · Cited by 71

Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation

Zahir, H., McCaughan, G. W., Gleeson, M., Nand, R. A., & McLachlan, A. J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200410000-00008 · Cited by 69

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype

Pallet, N., Étienne, I., Büchler, M., Bailly, É., de Ligny, B. H., Choukroun, G. J., Colosio, C., Thierry, A., Vigneau, C. M., Moulin, B., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13788 · Cited by 68

Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry

Adam, R. A., Karam, V. H., Delvart, V., Trunečka, P., Samuel, D., Bechstein, W. O., Němec, P., Tisone, G., Klempnauer, J. L., Rossi, M., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13171 · Cited by 67

Increased tacrolimus levels during diarrhea

Hochleitner, B. W., Bösmüller, C., Nehoda, H., Frühwirt, M., Simma, B., Ellemunter, H., Steurer, W., Hochleitner, E.-O., Königsrainer, A., & Margreiter, R. (2001) · Transplant International · doi:10.1007/s001470100331 · Cited by 67

Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans

Böhler, T., Nolting, J., Kamar, N., Gurragchaa, P., Reisener, K., Glander, P., Neumayer, H., Budde, K., & Klupp, J. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318030a40b · Cited by 66

Tacrolimus Inhibits NF-κB Activation in Peripheral Human T Cells

Vafadari, R., Kraaijeveld, R., Weimar, W., & Baan, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060784 · Cited by 65

Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis

Koster, R. A., Greijdanus, B., Alffenaar, J. C., & Touw, D. J. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8415-2 · Cited by 63

Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear Cells

Capron, A., Musuamba, F. T., Latinne, D., Mourad, M., Lerut, J. P., Haufroid, V., & Wallemacq, P. E. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181905aaa · Cited by 62

Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: Application to cardiac transplant recipients

Lemaitre, F., Antignac, M., & Fernandez, C. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.02.011 · Cited by 61

Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells

Lemaitre, F., Blanchet, B., Latournerie, M., Antignac, M., Houssel‐Debry, P., Verdier, M., Dermu, M., Camus, C., Priol, J. L., Roussel, M., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.12.018 · Cited by 60

A Risk-Benefit Assessment of Tacrolimus in Transplantation

Winkler, M., & Christians, U. (1995) · Drug Safety · doi:10.2165/00002018-199512050-00006 · Cited by 60

Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring

Jusko, W. J. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00009 · Cited by 58

Pharmacodynamic Monitoring of Calcineurin Inhibition Therapy: Principles, Performance, and Perspectives

van Rossum, H. H., de Fijter, J. W., & PELT, J. V. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181c0eecb · Cited by 55

The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function

Kannegieter, N. M., Hesselink, D. A., Dieterich, M., Kraaijeveld, R., Rowshani, A. T., Leenen, P. J. M., & Baan, C. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170806 · Cited by 53

Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?

Capron, A., Haufroid, V., & Wallemacq, P. E. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.027 · Cited by 53

Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function

Han, S. S., Yang, S. H., Kim, M. C., Cho, J., Min, S., Lee, J. P., Kim, D. K., Ha, J., & Kim, Y. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153491 · Cited by 52

Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival

Gallagher, H. M., Sarwar, G., Tse, T., Sladden, T. M., Hii, E., Yerkovich, S. T., Hopkins, P. M., & Chambers, D. C. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.028 · Cited by 51

Individualized Monitoring of Nuclear Factor of Activated T Cells-Regulated Gene Expression in FK506-Treated Kidney Transplant Recipients

Sommerer, C., Zeier, M. G., Meuer, S. C., & Giese, T. (2010) · Transplantation · doi:10.1097/tp.0b013e3181dc13b6 · Cited by 50

Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance

Werk, A. N., Lefeldt, S., Bruckmueller, H., Hemmrich‐Stanisak, G., Franke, A., Roos, M., Küchle, C., Steubl, D., Schmaderer, C., Bräsen, J. H., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.210 · Cited by 46

Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors

Giese, T. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1043 · Cited by 44

Comparison of Pharmacokinetics and Pathology for Low-Dose Tacrolimus Once-Daily and Twice-Daily in Living Kidney Transplantation

Tsuchiya, T., Ishida, H., Tanabe, T., Shimizu, T., Honda, K., Omoto, K., & Tanabe, K. (2013) · Transplantation · doi:10.1097/tp.0b013e318296c9d5 · Cited by 44

15-Year Follow-up of a Multicenter, Randomized, Calcineurin Inhibitor Withdrawal Study in Kidney Transplantation

Roodnat, J. I., Hilbrands, L. B., Hené, R. J., de Sévaux, R. G. L., Gregoor, P. J. H. S., Gestel, J. A. K.-V., Konijn, C., van Zuilen, A. D., van Gelder, T., Hoitsma, A. J., et al. (2014) · Transplantation · doi:10.1097/01.tp.0000442774.46133.71 · Cited by 43

Pharmacodynamic Monitoring of Calcineurin Phosphatase Activity in Transplant Patients Treated with Calcineurin Inhibitors

Yano, I. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.150 · Cited by 42

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose

Andrews, L. M., de Winter, B. C. M., Tang, J., Shuker, N., Bouamar, R., van Schaik, R. H. N., Koch, B. C. P., van Gelder, T., & Hesselink, D. A. (2017) · Transplantation Direct · doi:10.1097/txd.0000000000000644 · Cited by 41

A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients

Boughton, O. R., Borgulya, G., Cecconi, M., Fredericks, S., Moreton‐Clack, M., & MacPhee, I. A. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12076 · Cited by 40

Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12

van Rossum, H. H., Romijn, F. P. H. T. M., Smit, N. P. M., de Fijter, J. W., & PELT, J. V. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.009 · Cited by 39

Effects of Itraconazole on Tacrolimus Blood Concentrations in a Renal Transplant Recipient

Capone, D., Gentile, A., Imperatore, P., Palmiero, G., & Basile, V. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18409 · Cited by 39

Blood Tacrolimus Levels and Calcineurin Phosphatase Activity Early after Renal Transplantation

Koefoed‐Nielsen, P., Gesualdo, M. B., Poulsen, J. H., & Jørgensen, K. A. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.020209.x · Cited by 39

Validation of Tacrolimus Equation to Predict Troughs Using Genetic and Clinical Factors

Passey, C., Birnbaum, A. K., Brundage, R. C., Schladt, D. P., Oetting, W. S., Leduc, R. E., Israni, A. K., Guan, W., Matas, A. J., & Jacobson, P. A. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.98 · Cited by 38

The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats

Yiğitaslan, S., Erol, K., & Ünel, Ç. Ç. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/35254 · Cited by 37

Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

Andrews, L. M., Riva, N., de Winter, B. C. M., Hesselink, D. A., de Wildt, S. N., Cransberg, K., & van Gelder, T. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1033397 · Cited by 36

Interaction Between Tacrolimus and Nefazodone in a Stable Renal Transplant Recipient

Olyaei, A. J., DEMATTOS, A. M., Norman, D. J., & Wm, B. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03160.x · Cited by 35

Consideration of the Ethnic Prevalence of Genotypes in the Clinical Use of Tacrolimus

Andrews, L. M., de Winter, B. C. M., van Gelder, T., & Hesselink, D. A. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0136 · Cited by 33

An UPLC–MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells

Pensi, D., Nicolò, A. D., Pinon, M., Calvo, P. L., Nonnato, A., Brunati, A., Perri, G. D., & D’Avolio, A. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.01.054 · Cited by 33

Conversion From Twice-Daily to Once-Daily Tacrolimus Does Not Reduce Intrapatient Variability in Tacrolimus Exposure

Shuker, N., Cadogan, M., van Gelder, T., Roodnat, J. I., Kho, M. M. L., Weimar, W. W., & Hesselink, D. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000136 · Cited by 32

Impaired NF-kB Activation in T Cells Permits Tolerance to Primary Heart Allografts and to Secondary Donor Skin Grafts

Zhou, P., Hwang, K. W., Palucki, D. A., Guo, Z., Boothby, M. R., Newell, K. A., & Alegre, M. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00033.x · Cited by 31

Pharmacodynamic Disparities in Tacrolimus-Treated Patients Developing Cytomegalus Virus Viremia

Sommerer, C., Zeier, M. G., Czock, D., Schnitzler, P., Meuer, S. C., & Giese, T. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318226dac7 · Cited by 31

Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes – a prospective study

Zahn, A. (2014) · Annals of Transplantation · doi:10.12659/aot.889809 · Cited by 30

Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood

Sellar, K. J., van Rossum, H. H., Romijn, F. P. H. T. M., Smit, N. P. M., de Fijter, J. W., & PELT, J. V. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.08.013 · Cited by 30

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ramos, J. R., Herrero, M. J., Bosó, V., Megías‐Vericat, J. E., Hervás, D., Poveda, J. L., Escrivá, J., Pastor, A., Solé, A., & Aliño, S. F. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920168 · Cited by 29

Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation

de Graav, G. N., Bergan, S., Baan, C. C., Weimar, W., van Gelder, T., & Hesselink, D. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000179 · Cited by 28

Update on the clinical utility of once-daily tacrolimus in the management of transplantation

Salas, M. A. P., & Srinivas, T. R. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55458 · Cited by 26

Reduced residual gene expression of nuclear factor of activated T cells‐regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation

Steinebrunner, N., Sandig, C., Sommerer, C., Hinz, U., Giese, T., Stremmel, W., & Zahn, A. (2014) · Transplant Infectious Disease · doi:10.1111/tid.12206 · Cited by 26

Meltdose Tacrolimus Pharmacokinetics

Baraldo, M. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.02.002 · Cited by 26

Development of a Simple and Rapid Method to Measure the Free Fraction of Tacrolimus in Plasma Using Ultrafiltration and LC-MS/MS

Stienstra, N. A., Sikma, M. A., van Dapperen, A. L., de Lange, D. W., & van Maarseveen, E. M. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000351 · Cited by 25

Phosphospecific flow cytometry for pharmacodynamic drug monitoring: Analysis of the JAK-STAT signaling pathway

Vafadari, R., Weimar, W., & Baan, C. C. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.12.023 · Cited by 24

A Transient Increase of Calcineurin Phosphatase Activity in Living-Donor Kidney Transplant Recipients with Acute Rejection

Fukudo, M., Yano, I., Katsura, T., Ito, N., Yamamoto, S., Kamoto, T., Ogawa, O., & Inui, K. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rg-026 · Cited by 24

Inhibitory Effect of Tacrolimus on p38 Mitogen-Activated Protein Kinase Signaling in Kidney Transplant Recipients Measured by Whole-Blood Phosphospecific Flow Cytometry

Vafadari, R., Hesselink, D. A., Cadogan, M., Weimar, W., & Baan, C. C. (2012) · Transplantation · doi:10.1097/tp.0b013e318250fc62 · Cited by 24

Development and Evaluation of a Simulation Procedure to Take Into Account Various Assays for the Bayesian Dose Adjustment of Tacrolimus

Saint‐Marcoux, F., Debord, J., Parant, F., Labalette, M., Kamar, N., Rostaing, L. P. E., Rousseau, A., & Marquet, P. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31820d6ef7 · Cited by 23

SEX AND ETHNICITY MAY CHIEFLY INFLUENCE THE INTERACTION OF FLUCONAZOLE WITH CALCINEURIN INHIBITORS12

Mathis, A. S., DiRenzo, T., Friedman, G. S., Kaplan, B. E., & Adamson, R. M. (2001) · Transplantation · doi:10.1097/00007890-200104270-00011 · Cited by 23

Effect of Mild Diarrhea on Tacrolimus Exposure

van Boekel, G. A. J., Aarnoutse, R. E., van der Heijden, J. J., Hoogtanders, K., & Hilbrands, L. B. (2012) · Transplantation · doi:10.1097/tp.0b013e3182629e13 · Cited by 20

Nuclear Factor of Activated T Cells–Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors

Sommerer, C., & Giese, T. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000234 · Cited by 20

Low Plasma Concentrations of Albumin Influence the Affinity Column–Mediated Immunoassay Method for the Measurement of Tacrolimus in Blood During the Early Period After Liver Transplantation

Tempestilli, M., Stasio, E. D., Basile, M. R., Elisei, F., Antonini, M., Ettorre, G. M., Iappelli, M., & Pucillo, L. P. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318279dfd2 · Cited by 16

Influence ofCYP3A5genotypes on tacrolimus dose requirement: age and its pharmacological interaction withABCB1genetics in the Chinese paediatric liver transplantation

Yang, T.-H., Chen, Y., Xue, F., Han, L., Shen, C.-H., Zhou, T., Luo, Y., Zhang, J., & Xia, Q. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12667 · Cited by 15

Calcineurin Activity in Tacrolimus-Treated Renal Transplant Patients Early After and 5 Years After Transplantation

Mortensen, D. M., Koefoed‐Nielsen, P., & Jørgensen, K. A. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.08.003 · Cited by 15

Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals

Miura, M., Masuda, S., Egawa, H., Yuzawa, K., & Matsubara, K. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00249 · Cited by 15

Pharmacokinetics and Pharmacodynamics in Renal Transplant Recipients Under Treatment With Cyclosporine and Myfortic

Brunet, M., Crespo, M., Millán, O., Serón, D., Torregrosa, V., Jiménez, O., Moreso, F., Martorell, J., Grinyo, J. M., & Oppenheimer, F. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.07.003 · Cited by 14

Development of tandem mass spectrometry-based creatinine measurement using dried blood spot for newborn mass screening

Nakano, M., Uemura, O., Honda, M., Ito, T., Nakajima, Y., & Saitoh, S. (2017) · Pediatric Research · doi:10.1038/pr.2017.56 · Cited by 13

Role of T-Cell-Specific Nuclear Factor κB in Islet Allograft Rejection

Porras, D., Wang, Y., Zhou, P., Molinero, L. L., & Alegre, M. (2012) · Transplantation · doi:10.1097/tp.0b013e31824d11d7 · Cited by 11

Belatacept

van Gelder, T., & Hesselink, D. A. (2016) · Transplantation · doi:10.1097/tp.0000000000001268 · Cited by 11

Causes and Consequences of the Worldwide Belatacept Shortage

Gabardi, S., & van Gelder, T. (2017) · Transplantation · doi:10.1097/tp.0000000000001763 · Cited by 11

Point: A Call for Advanced Pharmacokinetic and Pharmacodynamic Monitoring to Guide Calcineurin Inhibitor Dosing in Renal Transplant Recipients

van Rossum, H. H., Press, R. R., den Hartigh, J., & de Fijter, J. W. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.141135 · Cited by 9

Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients

Kannegieter, N. M., Shuker, N., Vafadari, R., Weimar, W., Hesselink, D. A., & Baan, C. C. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000264 · Cited by 6

Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group AB0-Incompatible Kidney Transplant Recipients

Shuker, N., de Man, F. M., de Weerd, A. E., van Agteren, M., Weimar, W. W., Betjes, M. G. H., van Gelder, T., & Hesselink, D. A. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000266 · Cited by 4

Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients

Straßl, R. P., Schiemann, M., Doberer, K., Görzer, I., Puchhammer‐Stöckl, E., Eskandary, F. A., Kikić, Ž., Gualdoni, G. A., Vossen, M. G., Rasoul‐Rockenschaub, S., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy306 · Cited by 139

Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial

Doberer, K., Schiemann, M., Straßl, R. P., Haupenthal, F., Dermuth, F., Görzer, I., Eskandary, F. A., Reindl‐Schwaighofer, R., Kikić, Ž., Puchhammer‐Stöckl, E., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15810 · Cited by 132

Tacrolimus Exposure Prediction Using Machine Learning

Woillard, J., Labriffe, M., Debord, J., & Marquet, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2123 · Cited by 112

Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome

Schijvens, A. M., ter Heine, R., de Wildt, S. N., & Schreuder, M. F. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3929-z · Cited by 89

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients

Straßl, R. P., Doberer, K., Rasoul‐Rockenschaub, S., Herkner, H., Görzer, I., Kläger, J. P., Schmidt, R. L. J., Haslacher, H., Schiemann, M., Eskandary, F. A., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz039 · Cited by 79

Progress in tacrolimus monitoring in organ transplantation : a multidisciplinary approach

Capron, A. (2010) · Digital Access to Libraries

Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?

van Gelder, T., & Hesselink, D. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.42 · Cited by 38

Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue

Sallustio, B. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733285 · Cited by 25

Tacrolimus—why pharmacokinetics matter in the clinic

Henkel, L., Jehn, U., Thölking, G., & Reuter, S. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1160752 · Cited by 40

Therapeutic drug monitoring of tacrolimus in kidney transplantation

Bansal, S. (2020) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_4_20 · Cited by 7